

Claims:

1. A pharmaceutical composition comprising:
 - (i) a drug component comprising at least one pharmaceutically acceptable salt of glycopyrrolate, at least one corticosteroid selected from group consisting of budesonide, beclomethasone, and beclomethasone dipropionate, fluticasone furoate and fluticasone propionate and optionally at least one long acting beta-2-agonist (LABA) selected from the group consisting of indacaterol, olodaterol, formoterol vilanterol and the pharmaceutically acceptable salts thereof; and
 - (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

2. The pharmaceutical composition of claim 1, wherein the composition contains less than 500 ppm, preferably less than 100 ppm, more preferably less than 50 ppm, still more preferably less than 10 ppm and especially less than 5 ppm of water based on the total weight of the pharmaceutical composition and less than 1000 ppm, preferably less than 500 ppm, more preferably less than 100 ppm and particularly less than 50 ppm of oxygen based on the total weight of the pharmaceutical composition.

3. The pharmaceutical composition of claim 1 or claim 2, wherein the at least one pharmaceutically acceptable salt of glycopyrrolate is glycopyrronium bromide.

4. The pharmaceutical composition of any one of the preceding claims, wherein the drug component additionally comprises the at least one long acting beta-2-agonist (LABA).

5. The pharmaceutical composition of any one of the preceding claims, wherein the at least one pharmaceutically acceptable salt of glycopyrrolate, the at least one corticosteroid and the at least one long acting beta-2-agonist (LABA) where present are in a micronized form.

6. The pharmaceutical composition of any one of the preceding claims, wherein at least 90 weight %, preferably at least 95 weight % and more preferably at least 99 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).